Shares of Shilpa Medicare will be highlighted as its subsidiary, Shilpa Pharma Lifesciences, obtained a certificate of suitability from European regulators for Desmopressin. This API is used in diabetes treatment. The certification marks a milestone for the company. Shilpa Medicare’s stock has increased notably in 2024 despite recent declines.
| Subscribe To Our Free Newsletter |
